gamma-aminobutyric acid has been researched along with Parkinson Disease, Secondary in 47 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study demonstrates that gabapentin improves rigidity, bradykinesia, and tremor of parkinsonism including both Parkinson's disease and Parkinson's syndrome." | 5.08 | Gabapentin for parkinsonism: a double-blind, placebo-controlled, crossover trial. ( Gruenthal, M; Mueller, ME; Olson, WH; Olson, WL, 1997) |
| "Gabapentin is a recently available anticonvulsant whose mechanism of action remains unknown." | 2.68 | Gabapentin for parkinsonism: a double-blind, placebo-controlled, crossover trial. ( Gruenthal, M; Mueller, ME; Olson, WH; Olson, WL, 1997) |
| "Tremor is currently ranked as the most common movement disorder." | 1.56 | Purkinje cell misfiring generates high-amplitude action tremors that are corrected by cerebellar deep brain stimulation. ( Brown, AM; Lin, T; Sillitoe, RV; van der Heijden, ME; White, JJ; Zhou, J, 2020) |
| "Manganese (Mn) is a well established neurotoxin associated with specific damage to the basal ganglia in humans." | 1.38 | Pathophysiology of manganese-associated neurotoxicity. ( Aschner, M; Criswell, SR; Dydak, U; Guilarte, TR; Racette, BA; Zheng, W, 2012) |
| "Ropinirole did not cause marked stereotypies." | 1.28 | Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist. ( Costall, B; Domeney, AM; Eden, RJ; Gerrard, PA; Harvey, CA; Kelly, ME; Naylor, RJ; Owen, DA; Wright, A, 1991) |
| "Ropinirole was weakly active at alpha 2-adrenoceptors and 5-HT2 receptors but inactive at 5-HT1, benzodiazepine and gamma-aminobutyric acid receptors or alpha 1 and beta-adrenoceptors." | 1.28 | Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist. ( Costall, B; Domeney, AM; Eden, RJ; Gerrard, PA; Harvey, CA; Kelly, ME; Naylor, RJ; Owen, DA; Wright, A, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (36.17) | 18.7374 |
| 1990's | 16 (34.04) | 18.2507 |
| 2000's | 5 (10.64) | 29.6817 |
| 2010's | 7 (14.89) | 24.3611 |
| 2020's | 2 (4.26) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, L | 1 |
| Ren, Y | 1 |
| Zeng, Z | 1 |
| Ren, H | 1 |
| Li, S | 1 |
| He, S | 1 |
| He, F | 1 |
| Li, X | 1 |
| Brown, AM | 1 |
| White, JJ | 1 |
| van der Heijden, ME | 1 |
| Zhou, J | 1 |
| Lin, T | 1 |
| Sillitoe, RV | 1 |
| Lyu, S | 1 |
| Guo, Y | 1 |
| Zhang, L | 1 |
| Wang, Y | 1 |
| Tang, G | 1 |
| Li, R | 1 |
| Yang, J | 1 |
| Gao, S | 1 |
| Ma, B | 1 |
| Liu, J | 1 |
| Lozovaya, N | 1 |
| Eftekhari, S | 1 |
| Cloarec, R | 1 |
| Gouty-Colomer, LA | 1 |
| Dufour, A | 1 |
| Riffault, B | 1 |
| Billon-Grand, M | 1 |
| Pons-Bennaceur, A | 1 |
| Oumar, N | 1 |
| Burnashev, N | 1 |
| Ben-Ari, Y | 1 |
| Hammond, C | 1 |
| Kim, SN | 1 |
| Doo, AR | 1 |
| Park, JY | 1 |
| Choo, HJ | 1 |
| Shim, I | 1 |
| Park, JJ | 1 |
| Chae, Y | 1 |
| Lee, B | 1 |
| Lee, H | 1 |
| Park, HJ | 1 |
| Cuomo, D | 1 |
| Martella, G | 1 |
| Barabino, E | 1 |
| Platania, P | 1 |
| Vita, D | 1 |
| Madeo, G | 1 |
| Selvam, C | 1 |
| Goudet, C | 1 |
| Oueslati, N | 1 |
| Pin, JP | 1 |
| Acher, F | 1 |
| Pisani, A | 1 |
| Beurrier, C | 1 |
| Melon, C | 1 |
| Kerkerian-Le Goff, L | 1 |
| Gubellini, P | 1 |
| Nandhu, MS | 1 |
| Paul, J | 1 |
| Kuruvilla, KP | 1 |
| Malat, A | 1 |
| Romeo, C | 1 |
| Paulose, CS | 1 |
| Bido, S | 1 |
| Marti, M | 1 |
| Morari, M | 1 |
| Du, J | 1 |
| Sun, ZL | 1 |
| Jia, J | 1 |
| Wang, X | 1 |
| Wang, XM | 1 |
| Racette, BA | 1 |
| Aschner, M | 1 |
| Guilarte, TR | 1 |
| Dydak, U | 1 |
| Criswell, SR | 1 |
| Zheng, W | 1 |
| McCormack, AL | 1 |
| Thiruchelvam, M | 1 |
| Manning-Bog, AB | 1 |
| Thiffault, C | 1 |
| Langston, JW | 1 |
| Cory-Slechta, DA | 1 |
| Di Monte, DA | 1 |
| Mytilineou, C | 1 |
| McNaught, KS | 1 |
| Shashidharan, P | 1 |
| Yabut, J | 1 |
| Baptiste, RJ | 1 |
| Parnandi, A | 1 |
| Olanow, CW | 1 |
| Zhao, XD | 1 |
| Zhou, XP | 1 |
| Liu, HH | 1 |
| Li, BM | 1 |
| Hu, XW | 1 |
| Li, FQ | 1 |
| You, BM | 1 |
| Casey, DE | 1 |
| Gerlach, J | 2 |
| Magelund, G | 1 |
| Christensen, TR | 1 |
| Logothetis, J | 1 |
| Paraschos, A | 1 |
| Frangos, E | 1 |
| Ananth, J | 1 |
| Lloyd, KG | 1 |
| Kopp, N | 1 |
| Jordan, D | 1 |
| Michel, JP | 1 |
| Pialat, J | 1 |
| Veisseire, M | 1 |
| Chazot, G | 1 |
| Tommasi, M | 1 |
| Levy, R | 2 |
| Herrero, MT | 3 |
| Ruberg, M | 2 |
| Villares, J | 1 |
| Faucheux, B | 2 |
| Guridi, J | 3 |
| Guillen, J | 2 |
| Luquin, MR | 3 |
| Javoy-Agid, F | 2 |
| Obeso, JA | 3 |
| Onofrj, M | 1 |
| Ferracci, F | 1 |
| Fulgente, T | 1 |
| Malatesta, G | 1 |
| Ghilardi, MF | 1 |
| Maneuf, YP | 2 |
| Mitchell, IJ | 1 |
| Crossman, AR | 4 |
| Brotchie, JM | 2 |
| Vila, M | 1 |
| Agid, Y | 1 |
| Hirsch, EC | 1 |
| Gerlach, M | 1 |
| Gsell, W | 1 |
| Kornhuber, J | 1 |
| Jellinger, K | 1 |
| Krieger, V | 1 |
| Pantucek, F | 1 |
| Vock, R | 1 |
| Riederer, P | 1 |
| Olson, WL | 1 |
| Gruenthal, M | 1 |
| Mueller, ME | 1 |
| Olson, WH | 1 |
| Winkler, C | 1 |
| Bentlage, C | 1 |
| Nikkhah, G | 1 |
| Samii, M | 1 |
| Björklund, A | 1 |
| Noda, S | 1 |
| Jackson-Lewis, V | 1 |
| Liberatore, G | 1 |
| Agostini, L | 1 |
| Firenze, C | 1 |
| Gallai, V | 1 |
| Piccinin, GL | 1 |
| Piccirilli, M | 1 |
| Rossi, A | 1 |
| Wolfarth, S | 1 |
| Eden, RJ | 1 |
| Costall, B | 1 |
| Domeney, AM | 1 |
| Gerrard, PA | 1 |
| Harvey, CA | 1 |
| Kelly, ME | 1 |
| Naylor, RJ | 1 |
| Owen, DA | 1 |
| Wright, A | 1 |
| Hikosaka, O | 1 |
| Robertson, RG | 2 |
| Graham, WC | 1 |
| Sambrook, MA | 2 |
| Snyder, SH | 1 |
| Clarke, CA | 1 |
| Boyce, S | 1 |
| Watanabe, R | 1 |
| Kish, SJ | 1 |
| Chang, LJ | 1 |
| Mirchandani, L | 1 |
| Shannak, K | 1 |
| Hornykiewicz, O | 1 |
| Arushanian, EB | 1 |
| Young, AB | 1 |
| Rondot, P | 2 |
| Bathien, N | 2 |
| Ziegler, M | 1 |
| Fournier, V | 1 |
| Morselli, PL | 1 |
| Brooks, BA | 1 |
| Fuchs, AF | 1 |
| Finocchio, D | 1 |
| Bennett, JP | 1 |
| Kosicka, B | 1 |
| Bugera, TE | 1 |
| Kittel, M | 1 |
| Smiałek, M | 1 |
| Carotti, A | 1 |
| Tomassetti, G | 1 |
| Lucciarini, L | 1 |
| Barone, G | 1 |
| Mugnai, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Double-blind Placebo-controlled Multicenter Proof-of-concept Trial to Assess the Efficacy and Safety of Bumetanide in Parkinson's Disease[NCT03899324] | Phase 2 | 40 participants (Anticipated) | Interventional | 2019-04-26 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for gamma-aminobutyric acid and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Current psychopathological theories of tardive dyskinesia and their implications for future research.
Topics: Acetylcholine; Adult; Aged; Animals; Antipsychotic Agents; Brain; Dopamine; Dyskinesia, Drug-Induced | 1982 |
The neuropathology of GABA neurons in extrapyramidal disorders.
Topics: Basal Ganglia Diseases; gamma-Aminobutyric Acid; Humans; Huntington Disease; Neurons; Parkinson Dise | 1980 |
[Delayed type malignant syndrome and Parkinson's syndrome due to tiapride, Reye-like syndrome induced by calcium hopantenate].
Topics: Animals; Antipsychotic Agents; Diagnosis, Differential; gamma-Aminobutyric Acid; Humans; Neuroleptic | 1999 |
Experimental basis of the therapy of Parkinson's disease and the cholinergic-dopaminergic equilibrium in basal brain nuclei.
Topics: Animals; Apomorphine; Basal Ganglia Diseases; Behavior, Animal; Brain; Carbachol; Caudate Nucleus; C | 1976 |
[Neuroleptic parkinsonism and tardive dyskinesia and methods of pharmacologically correcting these pathologic conditions (review)].
Topics: Animals; Antipsychotic Agents; Cats; Cholinergic Fibers; Corpus Striatum; Dopamine; Dyskinesia, Drug | 1985 |
4 trials available for gamma-aminobutyric acid and Parkinson Disease, Secondary
| Article | Year |
|---|---|
gamma-Acetylenic GABA in tardive dyskinesia.
Topics: 4-Aminobutyrate Transaminase; Adult; Aged; Alkynes; Aminocaproates; Antipsychotic Agents; Brain; Dop | 1980 |
Gabapentin for parkinsonism: a double-blind, placebo-controlled, crossover trial.
Topics: Acetates; Adult; Aged; Amines; Antiparkinson Agents; Cross-Over Studies; Cyclohexanecarboxylic Acids | 1997 |
Movement disorders in patients with coexistent neuroleptic-induced tremor and tardive dyskinesia: EMG and pharmacological study.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Corpus Striatum; Double-Blind Method; Dyskinesia, Dr | 1987 |
Therapeutic response to progabide in neuroleptic- and L-dopa-induced dyskinesias.
Topics: Adult; Aged; Antipsychotic Agents; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-I | 1987 |
38 other studies available for gamma-aminobutyric acid and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Comparative study of striatum GABA concentrations and magnetic resonance spectroscopic imaging in Parkinson's disease monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chromatography, High Pressure Liquid; Corpus | 2019 |
Purkinje cell misfiring generates high-amplitude action tremors that are corrected by cerebellar deep brain stimulation.
Topics: Animals; Cerebellum; Deep Brain Stimulation; Female; gamma-Aminobutyric Acid; Harmaline; Male; Mice; | 2020 |
Blockade of GABA transporter-1 and GABA transporter-3 in the lateral habenula improves depressive-like behaviors in a rat model of Parkinson's disease.
Topics: Animals; Anisoles; Behavior, Animal; Depression; Dopamine; Dose-Response Relationship, Drug; Electro | 2020 |
GABAergic inhibition in dual-transmission cholinergic and GABAergic striatal interneurons is abolished in Parkinson disease.
Topics: Acetylcholine; Action Potentials; Animals; Bumetanide; Chlorides; Cholinergic Agents; Cholinergic Ne | 2018 |
Combined treatment with acupuncture reduces effective dose and alleviates adverse effect of L-dopa by normalizing Parkinson's disease-induced neurochemical imbalance.
Topics: Acupuncture Therapy; Animals; Antiparkinson Agents; Brain Chemistry; Combined Modality Therapy; gamm | 2014 |
Metabotropic glutamate receptor subtype 4 selectively modulates both glutamate and GABA transmission in the striatum: implications for Parkinson's disease treatment.
Topics: Aminobutyrates; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Electrophysiology; | 2009 |
Enhanced glutamate, IP3 and cAMP activity in the cerebral cortex of unilateral 6-hydroxydopamine induced Parkinson's rats: effect of 5-HT, GABA and bone marrow cell supplementation.
Topics: Animals; Behavior, Animal; Bone Marrow Cells; Bone Marrow Transplantation; Cerebral Cortex; Cyclic A | 2011 |
Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Data Interpretation, Statistical; Dyski | 2011 |
[High-frequency electro-acupuncture stimulation modulates intracerebral γ-aminobutyric acid content in rat model of Parkinson's disease].
Topics: Acupuncture Therapy; Animals; Brain; Electroacupuncture; gamma-Aminobutyric Acid; Male; Motor Cortex | 2011 |
Pathophysiology of manganese-associated neurotoxicity.
Topics: Air Pollutants, Occupational; Animals; Aspartic Acid; Brain; Dopamine; gamma-Aminobutyric Acid; Huma | 2012 |
Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; Dopamine; Environm | 2002 |
Inhibition of proteasome activity sensitizes dopamine neurons to protein alterations and oxidative stress.
Topics: Acetylcysteine; Animals; Canavanine; Cell Survival; Cells, Cultured; Cysteine Proteinase Inhibitors; | 2004 |
[Changes of amino acids neurotransmitters in striatum of hemi-parkinsonian rhesus monkey after high frequency stimulation of subthalamic nucleus].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acids; Animals; Chromatography, High Pressure Li | 2007 |
Side effects in preventive maintenance therapy with neuroleptics with special emphasis on tardive dyskinesia.
Topics: Antipsychotic Agents; Chronic Disease; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Pa | 1981 |
[Topographic and chemical study of the GABA synthetizing enzyme in Parkinsonian syndromes].
Topics: Aged; Brain; Brain Chemistry; Female; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Humans; Male | 1983 |
Effects of nigrostriatal denervation and L-dopa therapy on the GABAergic neurons in the striatum in MPTP-treated monkeys and Parkinson's disease: an in situ hybridization study of GAD67 mRNA.
Topics: Aged; Aged, 80 and over; Animals; Corpus Striatum; Denervation; gamma-Aminobutyric Acid; Glutamate D | 1995 |
Effects of drug manipulations on anterior components of somatosensory evoked potentials in a parkinsonian animal model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cholinergic Antagonists; Electric Stimulation | 1994 |
On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus.
Topics: Animals; Bicuculline; Corpus Striatum; Drug Combinations; Efferent Pathways; Enkephalins; gamma-Amin | 1994 |
Origin of chorea-ballism and multisystem degeneration: pathophysiological implications.
Topics: Animals; Basal Ganglia Diseases; Chorea; Dopamine; Dystonia; gamma-Aminobutyric Acid; Globus Pallidu | 1993 |
Consequences of nigrostriatal denervation on the gamma-aminobutyric acidic neurons of substantia nigra pars reticulata and superior colliculus in parkinsonian syndromes.
Topics: Animals; Corpus Striatum; Denervation; Female; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Hum | 1996 |
A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal ganglia-thalamocortical circuits in Parkinson syndrome.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Basal Ganglia; Biomarkers; Cerebral Cortex; | 1996 |
The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease.
Topics: Animals; Basal Ganglia; Benzazepines; Benzoxazines; Dopamine Agonists; gamma-Aminobutyric Acid; Loco | 1997 |
Intranigral transplants of GABA-rich striatal tissue induce behavioral recovery in the rat Parkinson model and promote the effects obtained by intrastriatal dopaminergic transplants.
Topics: Animals; Apomorphine; Brain Tissue Transplantation; Cell Count; Dopamine; Dopamine Agonists; Female; | 1999 |
Effects of a unilateral stereotaxic injection of Tinuvin 123 into the substantia nigra on the nigrostriatal dopaminergic pathway in the rat.
Topics: Animals; Astrocytes; Behavior, Animal; Calcium Channel Blockers; Decanoic Acids; Dopamine; Environme | 2000 |
[Neurochemical aspects of Parkinson tremor].
Topics: Antiparkinson Agents; gamma-Aminobutyric Acid; Histamine; Humans; Levodopa; Parkinson Disease, Secon | 1979 |
Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenylyl Cyclases; Animals; Antiparkinson Agents; Bloo | 1991 |
Dopamine and basal ganglia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Dopamine; gamma-Aminobutyric A | 1991 |
Further investigations into the pathophysiology of MPTP-induced parkinsonism in the primate: an intracerebral microdialysis study of gamma-aminobutyric acid in the lateral segment of the globus pallidus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chromatography, High Pressure Liquid; Dialysi | 1991 |
Parkinson's disease. Fresh factors to consider.
Topics: Animals; DNA; Dopamine; gamma-Aminobutyric Acid; MPTP Poisoning; Nerve Growth Factors; Nerve Tissue | 1991 |
The role of striatopallidal neurones utilizing gamma-aminobutyric acid in the pathophysiology of MPTP-induced parkinsonism in the primate: evidence from [3H]flunitrazepam autoradiography.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Brain; Carbidopa; Corpus Str | 1990 |
[Consciousness disorders in the aged due to therapeutic drugs].
Topics: Aged; Anemia; Cognition Disorders; Consciousness Disorders; Drug Interactions; Flunarizine; gamma-Am | 1990 |
Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers.
Topics: Aged; Aspartic Acid; Basal Ganglia Diseases; Brain; Bulbar Palsy, Progressive; Choline O-Acetyltrans | 1985 |
Pathophysiological mechanisms underlying tardive dyskinesia.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Brain; Dyskinesia, Drug-Induced; gamma-Aminobutyric Ac | 1985 |
Progressive supranuclear palsy: postmortem chemical analysis.
Topics: Basal Ganglia; Brain; Bulbar Palsy, Progressive; Choline O-Acetyltransferase; Dopamine; gamma-Aminob | 1985 |
Saccadic eye movement deficits in the MPTP monkey model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Eye Movements; gamma- | 1986 |
Striatal dopamine depletion, dopamine receptor stimulation, and GABA metabolism: implications for the therapy of Parkinson's disease.
Topics: Animals; Corpus Striatum; Dopamine; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Hydroxydopamin | 1986 |
[Gamma-aminobutyric acid (GABA) levels and glutamate decarboxylase (GAD) activity of the brain of rats with extrapyramidal syndrome after acute manganese chloride poisoning].
Topics: Acute Disease; Brain Chemistry; Chlorides; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Humans; | 1985 |
[Trial use of L-dopa associated with a dopa-decarboxylase inhibitor in Parkinson's syndrome].
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Diphenhydramine; Drug Therapy, Combination; g | 1974 |